US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

6  7  8  9    11    13  14  15  
Cytokine Therapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... accumulated number of ceased drugs over the last years amount to another 8 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ...  |  read more...
USD 4,496
EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 312 drugs. Egfr1 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 6,746
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... differentiation, cell motility, and survival. Ligand binding to the four closely related members of this RTK family -epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4)-induces ...  |  read more...
USD 6,746
Hematological Cancers Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 765 hematological cancer drugs in 1629 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 230 drugs. Hematological Cancers ...  |  read more...
USD 8,996
ID Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 94 companies plus partners developing 96 ID pathway targeting drugs in ...  |  read more...
USD 2,246
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... drugs in 1307 developmental projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 152 drugs. Il-2 Signaling Pathway In Oncology ...  |  read more...
USD 6,746
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 724 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 81 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... 667 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 68 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
USD 6,746
Hemiplegia Global Clinical Trials Review, H1, 2014
6/20/2014 | published by: GlobalData
... relating to the clinical trials on Hemiplegia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  read more...
USD 2,500
Mild Cognitive Impairment Global Clinical Trials Review, H1, 2014
6/20/2014 | published by: GlobalData
... report provides elemental information and data relating to the clinical trials on Mild Cognitive Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across ...  |  read more...
USD 2,500
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 27 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
USD 2,246
A Global Product and Pipeline Analysis of Antiretroviral Drug Development for the Treatment of HIV/AIDS
7/3/2014 | published by: Frost & Sullivan
... treatment of HIV infection, marked an important advancement in antiretroviral therapy (ART), significantly enhancing efficacy and reducing pill burden. Research has continued to build on this innovation, and patients now have at their disposal a ...  |  read more...
USD 4,000
Warts - Pipeline Review, H1 2014
6/15/2014 | published by: Global Markets Direct
... Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It ...  |  read more...
USD 2,000
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 28 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
USD 4,496
Immunotherapy in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 596 companies plus partners developing 1094 cancer immunotherapy drugs in 2802 developmental projects in cancer. In addition, there are 19 ...  |  read more...
USD 11,025
Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors. There are today 252 companies plus ...  |  read more...
USD 6,746
Leukemia Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there are 5 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 127 drugs. Leukemia Drug Pipeline Update lists all drugs and gives ...  |  read more...
USD 6,746
Global Alzheimer's Drugs Market 2014-2018
6/20/2014 | published by: TechNavio - Infiniti Research Ltd.
... Laboratories Inc., Janssen Pharmaceuticals Inc., Novartis AG, Adamas Pharmaceuticals Inc., Archer Pharmaceuticals Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., FORUM Pharmaceuticals Inc., H. Lundbeck A/S, Merck & Co., Inc., MorphoSys AG, Otsuka Pharmaceutical ...  |  read more...
USD 3,000
A Product and Pipeline Analysis of the Global Hepatitis C Virus (HCV)- Antiviral Market
6/19/2014 | published by: Frost & Sullivan
... need for curative therapy in the absence of a preventative vaccine. A treatment revolution is underway as the market moves away from protease inhibitors and interferon regimens and toward highly-effective, easily tolerated interferon-free oral therapies, ...  |  read more...
USD 5,000
Lung Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe ...  |  read more...
USD 6,746
Reperfusion Injury - Pipeline Review, H1 2014
6/25/2014 | published by: Global Markets Direct
... therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news ...  |  read more...
USD 2,000
Mitochondrial Drugs in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... the differences in mitochondrial functions between tumor and normal cells can be the key to design selective anti-cancer therapies. Compounds that directly affect mitochondrial functions are considered to present a promising alternative approach to eradicate ...  |  read more...
USD 6,746
Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 138 drugs. Modulators Of The Actin Cytoskeleton For The Treatment Of Cancer Drug Pipeline ...  |  read more...
USD 6,746
mTOR Signaling Pathway in Oncology Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... several hallmarks of cancer such as cell growth and proliferation, angiogenesis, and bioenergetics. Since mTOR acts as a neoplastic switch that is frequently turned on by many mutations found in cancer, inhibition of mTOR may ...  |  read more...
USD 6,746
NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2014
7/15/2014 | published by: BioSeeker Group AB
... more than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. There are today 87 companies plus partners developing 75 NOD-like receptor signaling pathway targeting drugs in 239 developmental ...  |  read more...
USD 4,496
6  7  8  9    11    13  14  15